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Recent evidence has shown that P. gingivalis, a Gram-negative, anaerobic oral 
bacterium, is negatively associated with the presence and outcome of esophageal 
squamous cell carcinoma (ESCC). While potential underlying mechanisms are yet 
to be established, P. gingivalis infection is known to inhibit apoptosis in gingival 
epithelial cells. Therefore, we hypothesized that P. gingivalis may also inhibit of 
the induction of apoptosis in human ESCC cells exposed to the commonly 
employed anti-ESCC chemotherapeutic agent, cisplatin. The capacity of P. 
gingivalis, at variant multiplicities of infection, to suppress cisplatin-induced 
necrosis and apoptosis in EC9706 ESCC cells was established by lactate 
dehydrogenase (LDH) release assays, caspase-3-specific Western blots and 
activated caspase-3 ELISAs. LDH and activated caspase-3 levels were found to be 
significantly decreased by P. gingivalis for necrosis and apoptosis respectively, 
indicating that chemotherapeutic drug action in ESCC is rendered ineffective in 
presence of P. gingivalis. This study provides some of the first mechanistic insights 
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CHAPTER 1:   INTRODUCTION 
1.1 Epidemiology of Esophageal Cancer 
Esophageal cancer is cancer arising from the esophagus - the food pipe that 
runs between the throat and the stomach. Esophageal carcinoma affects more 
than 450,000 people worldwide and the prevalence is rapidly expanding 
(Pennathur, Gibson, Jobe, & Luketich, 2013). Currently, esophageal carcinoma is 
the eighth most common incident cancer in the world (Zhang, 2013).  It is a 
growing health concern that is expected to increase in incidence over the next 10 
years (Napier, Scheerer, & Misra, 2014). The American Cancer Society estimates 
that 16,940 new cases of esophageal cancer will be diagnosed and 15,690 people 
suffering from the disease will die in 2017 in the United States alone. Untreated 
esophageal carcinoma can cause difficulty in swallowing, chest pain, weight loss, 
vomiting, bleeding into esophagus and upper airway obstruction making it a 
significant problem. It is one of the least studied and deadliest cancers worldwide 
because of its extremely aggressive nature and poor survival rate (Zhang, 2013). 
The five year survival rate for the cancer that has spread to the organs or lymph 
nodes away from the tumor (distant) is as low as 4%, for the cancer that has spread 
to nearby surrounding lymph nodes or tissues (regional) is 21% and for localized 
is 40% (American Cancer Society 2016). Factors such as age, gender, heredity, 
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gene mutation, chemical exposure, diet, etc. have been reported as risk factors 
for esophageal cancer. Two major histological subtypes of esophageal cancer are 
known. Squamous cell carcinoma (ESCC) arises from squamous cells, the thin, flat 
cells lining the esophagus, most often found in the upper and middle part of the 
esophagus and is more prevalent among the developing nations. Adenocarcinoma 
(EAC), which arises from the glandular (secretory) cells in the lining of the 
esophagus that release mucus, forms in the lower part of the esophagus, near the 
stomach and is more prevalent in developed nations, including the United States 
(Gao et al., 2016).  
 
Fig 1. A, Adenocarcinoma; B, Squamous cell carcinoma of the esophagus; Aˈ, 
Bˈ, corresponding endoscopic views.  
Illustration Copyright© 1998-2003 by The Johns Hopkins Health System 
Corporation and The Johns Hopkins University; used with permission from the 
Johns Hopkins Division of Gastroenterology and Hepatology 





1.2 Treatment of Esophageal Squamous Cell Carcinoma  
Traditionally, surgery is considered the best treatment for esophageal 
squamous cell carcinoma in terms of long-term survival. Several factors, including 
the type and stage of cancer, possible side effects, and the patient’s precedence 
and overall health help in choosing the treatment options and recommendations. 
Peculiarly for squamous cell cancer, chemotherapy and radiation therapy, a 
combination called chemoradiotherapy, are routinely recommended as the initial 
treatment to reduce the tumor in size, with surgery subsequently depending how 
well chemoradiotherapy worked.  
In Japan, surgical resection was the mainstay of treatment for ESCC. In 2008, 
Japan Clinical Oncology Group (JCOG 9907) conducted a study comparing 
postoperative and preoperative chemotherapy with cisplatin and 5-fluorouracil 
(5-FU) in patients with clinical stage II or III ESCC. Preoperative chemotherapy was 
found to be superior to postoperative by inducing down staging and residual 
tumor reduction and improving overall survival of the patient without additional 
serious adverse events. Since the results of the Japan Clinical Oncology Group 
(JCOG) 9907 study were reported, neoadjuvant chemotherapy with cisplatin plus 
5-fluorouracil followed by surgery has emerged as a new standard treatment 
(Higuchi et al., 2009). 
Chemotherapy is a treatment, or combination of drugs, that circulates 
throughout the body to kill cancer cells wherever they may be. It is well 
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documented that most cytotoxic anticancer agents work by inducing apoptosis 
and the disruption of the apoptotic program can render the treatment ineffective 
(Lowe & Lin, 2000). Among the chemotherapeutic drugs, one of the most widely 
and clinically used drug is cisplatin. Cisplatin is a platinum coordination complex 
that is hydrolyzed intracellularly to produce a highly reactive moiety which causes 
cross linking of DNA. It cross-links DNA in several different ways, interfering with 
cell division by mitosis. The damaged DNA elicits DNA repair mechanisms, which 
in turn activate apoptosis when repair proves impossible (Dasari & Tchounwou, 
2014). 
1.3 Apoptosis  
Apoptosis is a process of programmed cell death that occurs in multicellular 
organisms. Different biochemical events lead to characteristic morphological cell 
changes such as blebbing, cell shrinkage, nuclear fragmentation, chromatin 
condensation, chromosomal DNA fragmentation which ultimately lead to cell 
death (Ziegler & Groscurth, 2004). 
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Fig 2. Morphological changes in cells in progression from normal to apoptotic.  
Apoptosis can be initiated through one of two main understood pathways, 
intrinsic or extrinsic. In the intrinsic pathway the cell kills itself because it senses 
cell stress, while in the extrinsic pathway the cell kills itself because of signals from 
other cells. Both pathways initiate cell death by activating caspases, which are cell 
cycle-related proteases. The two pathways both activate initiator caspases, which 
then activate executioner caspases, which then kill the cell by degrading proteins 
indiscriminately. Most chemotherapeutic agents act by initiating the extrinsic 
apoptosis pathway in cancer cells. For example, 5-fluorouracil (5-FU) is converted 
in the body to the corresponding nucleotide, 5-fluoro-2-deoxy-uridine 
monophosphate (FdUMP), which inhibits thymidylate synthase and blocks the 
conversion of deoxyuridilic acid to deoxythymidylic acid interfering with the DNA 
replication or mis-incorporate into DNA or RNA ultimately causing cell apoptosis 
(Longley, Harkin, & Johnston, 2003). Similarly, cisplatin is hydrolyzed 
intracellularly to produce a highly reactive moiety which causes cross linking of 
DNA. It cross-links DNA in several different ways, interfering with cell division 
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by mitosis. The damaged DNA elicits DNA repair mechanisms, which in turn 
activate apoptosis when repair proves impossible (Dasari & Tchounwou, 2014). 
Another chemotherapeutic agent, docetaxel, a member of the taxane drug class, 
binds to microtubules which stabilizes them and prevents depolymerization from 
calcium ions. Inhibition of the disassembly of the microtubules results in 
accumulation of microtubules inside the cell and initiation of apoptosis.   
 
Figure 3. Apoptotic pathways: the extrinsic pathway involves so-called death 
receptors (CD95, TRAIL); the intrinsic one involves mitochondrial granules. Both 
pathways converge at caspase-3 activation, where classic biochemical and 
morphological changes in association with the apoptotic phenotype are 
originated.  
Illustration Copyright © 2010 ARÁN EDICIONES, S. L. by REVISTA ESPAÑOLA DE 
ENFERMEDADES DIGESTIVAS; used with permission from 
(http://scielo.isciii.es/img/revistas/diges/v102n1/punto_vista_f3.jpg). Illustration 
created by Calvino Fernandez, M. and T. Parra Cid. "H. pylori and mitochondrial 





1.3.1 Caspases including Caspase-3 
Caspases (cysteine-aspartic proteases) are a family of proteolytic enzymes 
playing essential roles in programmed cell death (including apoptosis, pyroptosis 
and necroptosis) and inflammation. They are termed caspases because of their 
specific cysteine protease activity - a cysteine in its active 
site nucleophilically attacks and cleaves a target protein only at the C-terminal of 
an aspartic acid amino acid.  
Apoptotic caspases are subcategorized as: 
1. Initiator Caspases (Caspase- 2, Caspase- 8, Caspase-9, Caspase- 10) 
2. Executioner Caspases (Caspase- 3, Caspase- 6 and Caspase- 7)  
Once initiator caspases are activated, they produce a chain reaction, 
activating several other executioner caspases. Executioner caspases degrade over 
600 cellular components in order to induce the morphological changes for 
apoptosis (Sollberger, Strittmatter, Garstkiewicz, Sand, & Beer, 2014). 
 
1.3.2 Activation of caspases  
Caspases are synthesized as inactive zymogens (pro-caspases) that are 
activated only in response to an appropriate stimulus. This post-translational level 
of control allows rapid and tight regulation of the enzyme. 
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Activation consists of dimerization and often oligomerization of pro-caspases, 
followed by cleavage into a small subunit and large subunit. The large and small 
subunit link with each other to form an active heterodimer caspase. The active 
enzyme often exists as a heterotetramer in the biological environment, where a 
pro-caspase dimer is cleaved together to form a heterotetramer (Shi, 2004). 
Once appropriately dimerized, caspases cleave at inter-domain linker 
regions, forming a large and small subunit. This cleavage allows the active-site 
loops to take up a conformation favorable for enzymatic activity (Riedl & Shi, 
2004). Initiator caspases cleave auto-proteolytically whereas executioner 
caspases are cleaved by initiator caspases. This chain of command allows an 
amplifying chain reaction or cascade for degrading cellular components, during 
controlled cell death. 
 




Fig 4. Capsase-3 activation: Executioner caspases can constitutively exist as 
homodimers. The red cuts represent regions where initiator caspases can cleave 
the executioner caspases. The resulting small and large subunit of each caspase-3 
will associate, resulting in a heterotetramer (Lavrik et al., 2003). 
Illustration Copyright© 2016 by Wikimedia Commons, the free media repository; 
used with permission from Creative Commons Attribution-Share Alike 4.0 
International (https://commons.wikimedia.org/wiki/File:Caspase_3_final.png). 
Illustration created by Tsgupta 
 
 
 Fig 5. PDB image of Caspase- 3 (4QTX) in ‘biological assembly’. Two shades of 
blue used to represent the two small subunits, while two shades of purple represent 
the two large subunits.  
Illustration Copyright© 2016 by Wikimedia Commons, the free media 
repository; used with permission from Creative Commons Attribution-Share Alike 
4.0 International (https://commons.wikimedia.org/wiki/File:Cas4_pdb.png). 
Illustration created by Tsgupta. 
 
1.4 Necrosis  
Necrosis is a form of cellular injury which results in premature cell death. It is 
caused by factors external or internal to the cell. In contrast to apoptosis, which 
follows defined signal transduction pathways, cellular death due to necrosis 
results in activation of various receptors, loss of cell membrane integrity and an 
10 
 
unrestrained release of products into the extracellular space (Proskuryakov, 
Konoplyannikov, & Gabai, 2003). Cellular changes that occur during this process 
are cell swelling followed by blebbing, nuclear shrinkage, chromatin condensation 
and finally dissolution of the nucleus into the cytoplasm (Kroemer et al., 2009). 
This process of cell death is almost always detrimental to the tissues and can be 
fatal because unlike apoptosis, cell membrane integrity is lost in necrosis and 
there is an uncontrolled release of cellular products into the extracellular space 
which initiates an inflammatory response in the adjacent tissues attracting 
leukocytes and phagocytes to eliminate the dead cells. The damaging substances 
released by the leukocytes keeps a check on the microbes as well as creates 
collateral damage to the surrounding tissues. Lactate dehydrogenase (LDH) is a 
cytosolic enzyme present in many different cell types. It catalyzes the conversion 
of pyruvate, the final product of glycolysis, to lactate with conversion of NAD+ to 
NADH and lactate to pyruvate. Plasma membrane damage during necrosis 
releases LDH into the extracellular space. Thus we have employed caspase-3 in 
the study as a means for detection of apoptosis and LDH release as a means for 
detection of necrosis. 
1.5 Bacteria and Cancer 
After it has been found that Helicobacter pylori can cause gastric 
adenocarcinoma, numerous other relationships between specific bacteria and 
cancer have been documented (De Koster, Buset, Fernandes, & Deltenre, 1994; 
Kim, Ruiz, Carroll, & Moss, 2011). For example, Salmonella typhi with gall bladder 
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cancer (Randi, Franceschi, & La Vecchia, 2006), Chlamydophila pneumoniae with 
lung cancer (Littman, Jackson, & Vaughan, 2005), Streptococcus bovis and 
Escherichia coli with colon cancer (Boleij, van Gelder, Swinkels, & Tjalsma, 2011; 
Prorok-Hamon et al., 2014), Porphyromonas gingivalis with oral squamous cell 
carcinoma etc (Katz, Onate, Pauley, Bhattacharyya, & Cha, 2011).  
 Evidence for a potential role for microbes in the development of 
esophageal cancer has recently emerged. A study by Pei et al. concluded 
Streptococcus, Prevotella and Veillonella to be the most commonly detected 
microbial genera in esophageal biopsies (Pei et al., 2004; Pei et al., 2005). Another 
study by Yang et al. have categorized the microorganisms found in the esophagus 
into two subtypes: the Streptococcus-dominated type I microbiome, and the 
Gram-negative dominated type II microbiome. Type I is associated with normal 
esophagus whereas type II with Barrett’s esophagus and esophagitis. 16S rRNA 
gene survey of the biopsy revealed these microbiome types located 
predominantly in these histological esophageal phenotypes (Yang et al., 2009). A 
significant association of esophageal squamous dysplasia, a precursor lesion of 
esophageal squamous cell carcinoma with the colonizers of the upper digestive 
tract microbiota has also been reported as these bacterial communities were 
characterized by 16S rRNA gene survey in biopsy samples taken from the dysplasia 
of the distal esophagus (Yang, Francois, & Pei, 2012). Very limited studies have 
been done on the esophageal microbiota (at the species level) in patients suffering 
from ESCC. Recent evidence suggests that the oral pathogen, Porphyromonas 
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gingivalis, is epidemiologically associated with ESCC as immunohistochemical 
detection of P. gingivalis, expression of P. gingivalis protease lysine-gingipain and 
P. gingivalis-specific 16S rDNA was significantly higher in esophageal cancerous 
and adjacent tissue as compared to the normal esophageal mucosa. In addition, 
Kaplan-Meier survival analysis showed that the higher expression of P. gingivalis 
whole cell antigens or lys-gingipain were both positively related with lower mean 
survival time of patients with ESCC. Hence the study indicates that the P. gingivalis 
infection could be a novel risk factor for ESCC.  
 
1.6 Porphyromonas gingivalis and Esophageal Cancer 
Porphyromonas gingivalis is a Gram-negative, proteolytic, asaccharolytic 
anaerobe.  It is one of the members of the microbiota responsible for chronic and 
severe manifestations of the periodontal disease. According to the American 
Academy of Periodontology, periodontal disease is an inflammatory disease that 
affects the soft and hard structures that support the teeth. In its early stage, called 
gingivitis, the gums become swollen and red due to inflammation, which is the 
body’s natural response to the presence of harmful bacteria. In the more serious 
form of periodontal disease called periodontitis, the gums pull away from the 
tooth and supporting gum tissues are destroyed. Bone can be lost, and the teeth 
may loosen or eventually fall out. P. gingivalis is a keystone oral pathogen, in mice, 
capable of invading the epithelial cells and manipulating the native immune 
system and cell cycle machinery of the host (Hajishengallis & Lamont, 2014; 
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Whitmore & Lamont, 2014). It has been shown that P. gingivalis localizes itself in 
the perinuclear region of the gingival epithelial cells (GECs) once invaded (Belton, 
Izutsu, Goodwin, Park, & Lamont, 1999) and is capable of inhibiting the apoptosis 
of the GECs (Nakhjiri et al., 2001). Several studies have established that 
periodontal diseases and tooth loss are related with oral cancer, gastric cancer 
and pancreatic cancer and may even relate to survival (Whitmore and Lamont 
2014). P. gingivalis can induce the expression of the B7-H1 and B7-DC receptors  
in oral squamous cell carcinoma (OSCC) cells which contribute to chronic 
inflammation and supress effector T cells contributing to immune evasion by oral 
cancer. P. gingivalis infection also activates several pathways which induce MMP-
9 expression and promotes carcinoma cell migration and invasion in the context 
of OSCC (Whitmore and Lamont 2014). In a prospective cohort study of over 400 
cases and controls, >2 fold increase in risk of pancreatic cancer was observed 
among those with high levels of antibodies to P. gingivalis after adjusting for 
known risk factors (Michaud, 2013). Greater serum P. gingivalis IgG, independent 
of periodontal disease, inclined to be associated overall with increased 
orodigestive cancer mortality in a prospective cohort study of 12,605 subjects of 
the National Health and Nutrition Examination Survery III (NHANES III) survey 
(Ahn, Segers, & Hayes, 2012).  In the context of oral squamous cell carcinoma, P. 
gingivalis-mediated immune avoidance, apoptosis impedance, carcinogen 
conversion, induction of MMP-9 and dysbiosis of the oral microbiota have all been 
posited as pro-tumorigenic mechanisms (Inaba et al., 2014; Whitmore & Lamont, 
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2014). A recent study by Gao et al. has shown that P. gingivalis is negatively 
associated with the presence and outcome of esophageal squamous cell 
carcinoma (ESCC) as described above. To date, however, the potential 
mechanisms by which the important oral pathogen, Porphyromonas gingivalis, 
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CHAPTER 2:  MATERIALS AND METHODS 
2.1 Materials and Vendors 
EC9706 cell line was gifted by Dr. Zhan Qimin (State Key Laboratory of Molecular 
Oncology, Chinese Academy of Medical Science, Beijing, China). (Rosewell Park 
Memorial Institute) RPMI-1640 (Gibco 11875-093) medium was purchased from 
Thermo Fisher Scientific (Rockford, IL). Sodium pyruvate 100mM, 2-
Mercaptoethanol and Dimethyl Sulfoxide (DMSO) were purchased from Sigma-
Aldrich (St. Louis, MO). Fetal Bovine Serum, penicillin (10,000 U/ml) and 
streptomycin (10,000 µg/ml) were purchased from Atlanta Biologicals (Flowery 
Branch, GA). HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) 20mM  
was from Fisher Scientific (Fair Lawn, NJ), sodium bicarbonate 7.5% from Life 
Technologies Corporation (Grand Island, NY) and Plasmocin Prophylactic 
(2.5mg/ml – stock solution) was purchased from InvivoGen (San Diego, CA). Tissue 
culture treated flasks 25cm2 and 75cm2 were purchased from Corning 
Incorporated (Corning, NY. 
Porphyromonas gingivalis ATCC 33277 (Pg) strain was originally obtained from the 
American Type Culture Collection. Gifu anaerobic medium (GAM), was purchased 
from Nissui Pharmaceutical (Tokyo, Japan). 
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Phosphate buffered saline (PBS) was from Thermo Fisher Scientific (Rockford, IL) 
Trypsin 0.25% was from Sigma Aldrich (St. Louis, MO). Cisplatin was purchased 
from EMD Millipore Corporation (Billerica, MA). 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) reagent was 
purchased from Sigma Aldrich (St. Louis, MO),  sodium dodecyl sulfate (SDS) – 10% 
(w/v) from Bio-Rad laboratories (Hercules, CA) and 0.5M hydrochloric acid (HCL) 
from Fisher Scientific (Fair Lawn, NJ). 
Pierce LDH Cytotoxicity Assay Kit was purchased from Thermo Scientific 
(Rockford). Alexa Fluor® 488 Annexin V/Dead Cell Apoptosis Kit came from 
Thermo Fisher Scientific (Waltham, MA). 
Caspase-3 antibody (#9662), β-Actin antibody (#8457 S), and anti-rabbit HRP-
tagged and RIPA lysis buffer were purchased from Cell Signaling Technology 
(Beverly, MA).  Phosphatase inhibitors 2 and 3, proteinase inhibitor cocktail and 
phenylmethylsulfonyl fluoride (PMSF)-serine protease inhibitor from Sigma 
Aldrich (St. Louis, MO).  EDTA (0.5 M) was from Hoefer Inc. (San Francisco, CA). 28 
½ gauge insulin syringes were purchased from Beckton Dickinson & Company 
(Franklin Lakes, NJ). Pre-cast gels (NuPAGETM 4-12% Bis-Tris Gel 1.5mm x 15well), 
MES SDS running buffer (20X) NP0006-1, transfer buffer 20X NP0002, See Blue 
plus and antioxidants were from Life Technologies (Carlsbad, CA). Cell scrapers 
25cm were purchased from Sarstedt (Newton, NC). Magic Mark was purchased 
from Invitrogen (Carlsbad, CA). Tris buffered saline (TBS) – 10X and Tween 20 were 
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purchased from Fisher Scientific (Fair Lawn, NJ). Bovine serum albumin (BSA) came 
from Millipore Corporation (Kankakee, IL). Polyvinylidene difluoride (PVDF) 
membrane 0.2µm and filter papers purchased from Bio-Rad Laboratories 
(Hercules, CA). WestPico Chemiluminescent substrate and Pierce BCA Protein 
Assay kit were purchased from Thermo Scientific (Rockford, IL). 
Human/Mouse Cleaved Caspase-3 (Asp 175) (DYC832-5) kit purchased from R&D 
Systems (Minneapolis, MN). 
 Methods 
2.2 Selection of Cells – EC9706 is considered one of the more stable esophageal 
cancer cell lines and is widely used in research studies. It represents poorly- 
differentiated esophageal squamous cell carcinoma (ESCC).  An alternative cell 
line, KYSE30, representing well-differentiated esophageal squamous cell 
carcinoma, was also considered for these studies. However, the stability of the 
KYSE series cell line is not well established, and the production of this series is no 
longer continuing. Considering these points, we proceeded further with the 
EC9706 cell line for our experiments. 
2.3 Esophageal Cancer Cell Culture – Esophageal Cancer cell line - EC9706 was 
maintained as frozen stocks in 10% DMSO at -800C.  Cells were cultured in RPMI-
1640, supplemented with 10% Fetal Bovine Serum, sodium pyruvate 100mM, 2-
mercaptoethanol, penicillin, streptomycin, HEPES buffer 20mM, sodium 
bicarbonate 7.5%. In addition, Plasmocin prophylactic was added at a 
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concentration of 5µg/ml to prevent mycoplasma.  The cells were incubated at 
370C, 5%CO2.   Culture was initially in 25cm2 cell culture flasks until reaching 70-
90% confluence. Subsequent passages were to 75cm2  flasks. 
2.4 P. gingivalis culture – P. gingivalis was maintained as frozen stock cultures and 
grown in GAM under anaerobic conditions (80% N2, 10% H2, and 10% CO2) at 370C 
in an anaerobic chamber. Bacterial cells were harvested at mid to late log phase 
(P. gingivalis- O.D at 600 nm =1.0, corresponding to 109 cells per ml). 
2.5 Assessment of EC9706 cancer cell apoptosis and necrosis- 
To enable us to assess the effects of Pg treatment on necrosis and apoptosis of 
EC9706 cells, it was first necessary to conduct several experiments to determine 
the effects of differing concentrations and length of exposure of cisplatin on % 
viability and proportion of cells in apoptosis.  Once we had established optimal 
conditions for these parameters we were able to narrow down the range of 
concentration and time and test the effects of Pg on these factors.  
2.5.1 Determination of viability of EC9706 
 Viability of EC9706 cells was assessed by colorimetric assay to determine extent 
of metabolic activity in cultures exposed to different dosages and exposure times 
of cisplatin compared to untreated cells.  Water soluble MTT (3-(4, 5-
Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium Bromide) was purchased in 
powder form and diluted in PBS to 12mM solution and stored at 40C. 10,000 cells 
were seeded in each well of a 96 well plate and incubated overnight. After 8h, 
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specific wells were infected with Pg at a Multiplicity of Infection (MOI) of 10:1 and 
100:1. RPMI-1640 media without antibiotics was used during addition of Pg and 
further. After 90 min of infection with Pg, the cells were washed with PBS three 
times and then exposed to cisplatin (0, 10, 100 and 500µM) for 12, 24, 36 and 48 
h. After the desired incubation times the microplate was centrifuged at 350 g (x 
1000) for 10 min and the supernatant was collected for LDH assay (see below). 
The cells attached to the bottom of the wells were used for MTT assay. 5ml of 
RPMI 1640 without phenol red was mixed with 500 µl of MTT reagent (12 mM) 
and 50 µl of this solution was added to each well containing the cells and 
incubated for 4 h. Next, 5ml of sodium dodecyl sulfate (SDS) was mixed with 100µl 
of 0.5M hydrochloric acid (HCL) and 50µl of this solution was added to each well 
and incubated for another 4 h.  The plate was read at 570nm by a 
spectrophotometer.  Viability was expressed as a function of OD/OD untreated 
cells. 
The cytotoxic effects of cisplatin treatment under different conditions was further 
assessed by lactate dehydrogenase (LDH) release assay using the Pierce LDH 
Cytotoxicity Assay Kit. 
Extracellular LDH in the media can be quantified by a coupled enzymatic reaction 
in which LDH catalyzes the conversion of lactate to pyruvate via NAD+ reduction 
to NADH.  Purified diaphorase added to the mixture uses NADH to reduce a 
tetrazolium salt (INT) to a red formazan product that can be quantified by 
absorption at 490nm. The level of formazan formation is directly proportional to 
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the amount of LDH released into the medium, which is indicative of cytotoxicity.  
We first determined the optimum cell number for the assay as per the manual. 
Serial dilution of cells (0-20,000 cells/100µl media) were plated in two sets of 
triplicate wells in a 96-well tissue culture plate. The plate was incubated overnight 
in an incubator at 37°C, 5% CO2. 10μL of sterile, ultrapure water was then added 
to one set of triplicates, and 10μL of lysis buffer (10X) to the other.   The plate was 
mixed by gentle tapping. After a further 45 min incubation at 37°C, 5% CO2, 50μL 
of each sample was transferred to a 96 well flat bottom plate and 50μL of reaction 
mixture (lyophilized substrate mix + 11.4ml of ultrapure water + 0.6ml of assay 
buffer) was added to each well. The plate was covered to protect from light, and 
incubated for 30 min at room temperature. 50μL of stop solution was added and 
the plate mixed by gentle tapping. Any bubbles present in the wells were broken 
by a syringe needle. The absorbance was measured at 490nm and 680nm. To 
determine LDH activity, the 680nm absorbance value (background signal from 
instrument) was subtracted from the 490nm absorbance.   
Once optimum cell number had been determined, this assay was used to 
determine the cytotoxic effects of cisplatin. 10,000 cells were seeded per well and 
appropriate concentrations of cisplatin were added to triplicate cultures. LDH 
activity was determined in the manner described above. Supernatants collected 





2.6 Assessment of Cancer Cell Apoptosis  
EC9706 cells were cultured in 12 well plates (cells/well). Pg (MOI 10:1; 100:1) and 
cisplatin (0, 10, 100, 500 µM) were added as described earlier.  After incubation 
(0-48h) cells were harvested using 0.25% trypsin, trypsin neutralized with culture 
media, and washed in cold PBS. Alexa Fluor® 488 Annexin V/Dead Cell Apoptosis 
Kit was used to label cells following manufacturer’s instructions. 
1X annexin-binding buffer was prepared by diluting 5X buffer with deionized 
water. Propidium iodide (PI) 5µg/ml stock solution was diluted to a working 
concentration of 100 µg/ml in annexin-binding buffer. 
The washed cells were re-centrifuged and re-suspended in annexin-binding buffer. 
5µl Alexa Fluor 488 annexin V and 1 µl 100 µg/ml PI working solution was added 
to each 100 µl of cell suspension. The tubes were incubated at room temperature 
for 15 min in the dark. After the incubation, 400 µl annexin-binding buffer was 
added, mixed gently and kept on ice. The stained cells were analyzed as quickly as 
possible by flow cytometry.  
Cleaved and uncleaved caspase-3 levels were detected by western blot. EC9076 
cells (50,000/well) were seeded into 12 well plates and incubated at 370C, 5% CO2. 
After 8h of incubation the cell culture media in the wells was replaced with fresh 
RPMI-1640 without antibiotics, and the cells were infected with Pg for 90 min at 
MOI of 100:1. The cells were then washed with PBS and exposed to Cisplatin 10µ 
M for different time periods (24-48h) as described above.  
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After incubation cultures were lysed in RIPA buffer (5 mM EDTA; SIGMA 
proteinase inhibitor cocktail, SIGMA phosphatase cocktails 2 and 3, and PMSF) 
taking care to collect both attached and floating cells. Supernatants containing 
detached cells were collected and centrifuged at 2.0 g (x 1000), 40C for 3 min, 
while remaining attached cells were washed in ice cold PBS. This PBS was used to 
re-suspend the cell pellets and centrifuge as before. Lysis buffer was added to 
attached cells in wells.  Wells were scraped with a cell scraper and lysate collected 
and added to pelleted cells.  Lysates were incubated on ice for 20 min and 
vortexed every 5 min. The DNA was sheared by passage through insulin syringe 
needle 7-8 x and the tubes centrifuged at max speed for 10 min to pellet debris. 
All steps were performed at 40C. The lysates were then aliquoted and frozen at -
200C.  
Protein levels were estimated using the Pierce BCA Protein Assay kit. Dilutions of 
each sample (50µl) were incubated in a 96 well plate with 50µl of the reagent 
mixture (Reagent A: Reagent B (50:1) and incubated at 370C for 30 min. A standard 
curve of serial 1/2 dilutions of BSA (1mg/ml) was prepared each time.  The optical 
density was then read at 562nm in a spectrophotometer and estimated protein 
concentration calculated.  
Culture extracts were separated by SDS-PAGE gel electrophoresis. Protein 
concentrations were normalized and 40 µg each sample denatured by 20 min 
incubation at 700C in 20 µl LB with reducing buffer. Samples were loaded onto pre-
cast NuPAGETM 4-12% Bis-Tris gels and run at 200V for 50 min in   MES-SDS running 
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buffer with NuPAGE antioxidant in the upper chamber.  To allow size 
differentiation, 5µl See Blue Plus + 5µl Magic Mark was loaded into the first well. 
The electrophoresis was stopped when the dye front reached the bottom of the 
gel. 
Proteins were transferred to PVDF membrane (0.2µm) pre-soaked in 100% 
methanol for 2-5 min. The gel was removed from casing and the blot module 
loaded in the following order: 2-3 sponges/filter paper/gel/PVDF/filter paper/3 
sponges. Sponges and filters were pre-soaked in ice cold transfer buffer containing 
10% methanol and 1% antioxidant.  The module was placed in the transfer unit 
and pre-cooled transfer buffer added to the assembly. The air bubbles were 
tapped out.  Ice cold water was added to the tank. The whole assembly was placed 
on ice and connected to the power supply to run at 35V for 2h. 
The blots were incubated with 5% powdered milk inTBS-Tween20 (0.1%) 
at room temperature for 1 hour. The blocking buffer was poured off and the 
membrane was washed 3 times for 5 min each with TBST. 
The membrane was incubated in primary antibody (Caspase-3) solution 
(1:1000 dilution in TBST 5% powdered non-fat dry milk), overnight at 40C with 
gentle shaking.   The blot was washed 3 times as before. Blots were then incubated 
in secondary anti-rabbit HRP-tagged antibody solution (1:2000 in 5% w/v nonfat 
dry milk) for 1 hour at room temperature. The blot was washed 3 times and then 
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incubated with WestPico Chemiluminescent substrate solution for 5min before 
imaging. 
 
2.6.1 Quantification of Cleaved Caspase-3 in Culture Lysates 
 Human/Mouse Cleaved Caspase-3 (Asp 175) (DYC832-5) kit was used. 
Overnight cultures of EC9706 cells (one million) in 6 well plates were infected with 
Pg (MOI – 10:1) and incubated for 8 h. Triplicate groups were treated with cisplatin 
10uM for 30, 36, 42, 48 and 54 hours together with control groups with no 
infection.  Cell extracts were prepared in lysis buffer (1mM EDTA, 0.5% Triton X-
100, 5mM NaF, 6M urea, proteinase inhibitor cocktail and phosphatase inhibitors) 
prepared according to manufacturer’s instructions  (R & D Human/Mouse Cleaved 
Caspase-3 (Asp 175) kit)  Protein concentrations were estimated as described 
previously. Lysate concentrations were equalized with 6M urea lysis buffer, 6-fold 
dilutions were prepared to reduce urea concentration to 1M.  Thereafter, further 
dilutions were made with 1M urea buffer. 
Samples were plated in 96-well microplate coated overnight with 100µl 
2ug/ml anti-total caspase 3 capture antibody.  The plate had been blocked with 
300µl of block buffer in each well for 1-2 hours. After a 2 hour incubation at room 
temperature, wells were washed 3 times and 100µl detection antibody (anti-
cleaved caspase-3 (150ng/ml) added to each.  After a further 2h incubation at 
room temperature, the aspiration/wash step was repeated. Streptavidin-HRP was 
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added to each well and incubated for 20 min at temperature, the plate being 
protected from direct light. Aspiration/wash step was repeated. 100µl of 
substrate solution was added to each well and incubated for 20 min at room 
temperature away from direct light. 50 µl of stop solution was added to each well 
and the optical density was determined immediately using microplate reader set 
to 450nm.  















CHAPTER 3: RESULTS 
 
 
3.1 Optimization of Cisplatin-induced Cancer Cell Death 
First, we determined the optimal concentration and exposure duration of the 
chemotherapeutic drug, cisplatin, to induce maximal apoptosis with minimum 
effective dose in EC9706 cells, in order to facilitate the subsequent assessment of 
the effect of P. gingivalis on drug-induced programmed cell death in these ESC 
cells. Cell viability and necrosis in cisplatin-exposed EC9706 cells was also 
assessed. 
 
Metabolic Activity of EC9706 cells is reduced at higher cisplatin concentrations 
To examine the anti-tumor potential of cisplatin on esophageal squamous 
carcinoma cells (EC9706), cell viability analysis was performed using the MTT 
assay. EC9706 cells were incubated with a wide range of cisplatin concentrations 
(0, 10, 100 and 250µM) for 48 hours. As shown in the Fig 6. cisplatin induced 
growth inhibition in a dose-dependent manner in EC9706 cells. In addition, kinetic 
analysis revealed that cisplatin (10µM) induced a significant growth inhibition 































































































Fig 6. Cisplatin inhibits EC9706 cell growth in a dose-dependent manner.  
EC9706 cells were treated with cisplatin (0, 10, 50, 100, 250µM) for 48h prior to 
assessing cell viability using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide (MTT) assay. Data are presented as the mean ± 
standard error of three individual experiments. Values are calculated by 
subtracting OD 570nm - OD 570nm of media blank and expressed as a percentage 
of no treatment control. 
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Fig 7. Cisplatin induces time-dependent cell growth inhibition in EC9706 cells.  
The cells were treated with Cisplatin (10μM) for 0-72h. The cell viability was 
determined using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide assay. Data are presented as the mean ± standard error of three 
individual experiments. Values are calculated by subtracting OD 570nm - OD 




3.2 Analysis of type of cell death by cisplatin 
Cisplatin-induced cell death was optimized by MTT as above. Since MTT gives us 
an idea about the relative metabolic activity of the cells and not the type of cell 
death, we had to analyze if cell death caused by cisplatin was due to apoptosis or 
necrosis. Several assays were performed to analyze the type of cell death.  
Detection of Cleaved Caspase-3 but not Annexin V labeling of EC9706 cells could 
reliably indicate cisplatin-induced apoptosis– EC9706 cells were detached with 
trypsin, accutase, cell dissociation media and scraping. Flow cytometry was 
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performed but background levels of apoptosis were too high to determine the 
contribution by cisplatin. 
Western blotting analysis and human active caspase-3 ELISA were performed to 
detect levels of cleaved caspase-3, an absolute biomarker of apoptosis, after 
different treatment regimes. These experiments indicated that cisplatin 10µM 
exposure for 42h caused maximum activated caspase-3 levels and the cells were 




Fig 8. Cisplatin 10 µM induces maximum apoptosis at 42h of treatment. 
Western blot of whole cell lysates of EC9706 cells treated with cisplatin (5, 10µM) 
for (12, 24, 42, 48, 54h). The cleaved and uncleaved caspase-3 levels were 
detected by caspase-3 primary antibody which showed cleaved caspase-3 peaked 
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Fig 9. Cisplatin treatment at 10µM induces maximum cleaved caspase-3 from 
EC9706 cells at 42h of treatment.  
EC9706 cells were treated with cisplatin 10µM for (30, 36, 42, 48h). Figure shows 
maximum cleaved caspase-3 levels at 42h of treatment with cisplatin 10µM. Data 
are presented as the mean ± standard error of three individual experiments. Cisp 
– cisplatin  
 
 
3.3 Cisplatin Induces Necrosis in EC9706 cells in a dose-dependent manner 
 
Cisplatin 10µM exposure for 42h caused maximum detectable cleaved caspase-3. 
(Fig. 9.)  To confirm that the cells were not necrotic at that dose and duration of 
cisplatin, the LDH assay was performed. The goal of this experiment is to optimize 
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concentration and duration of treatment of cisplatin to induce maximum number 































































































Fig 10. Cisplatin induces necrosis in EC9706 cells in a dose-dependent manner. 
EC9706 Cell LDH activity treated with cisplatin (10, 50, 100, 250, 500µM) for 48h. 
Cisplatin 10µM shows the least LDH release which indicates minimal necrosis. 
Data are presented as the mean ± standard error of three individual experiments. 
















































































































* * * *
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Fig 11.  Cisplatin 10µM induces necrosis in a time-dependent manner. 
Cisplatin induces time-dependent necrosis in EC9706 cells. The cells were treated 
with cisplatin (10μM) for different time periods (12-60h). Necrosis was 
determined using the lactate dehydrogenase (LDH) release activity assay. Data are 
representative of three individual experiments. Data are presented as the mean ± 
standard error of three individual experiments. Cisp - ciplatin 
 
Based on the above experiments, we see that lower concentrations of 
chemotherapeutic agent, here cisplatin 10µM, can cause a progressive increase in 
necrotic and apoptotic cells. The slow death response, maximizing the duration of 
exposure to a modest but effective concentration of agent rather than maximizing 
the concentration present for a short duration can be an optimal strategy for 
initiating apoptosis of cancer cells.  Use of the lowest effective dose will increase 




3.4 P. gingivalis Pre-treatment Inhibits Cisplatin induced Apoptosis and Necrosis 
 
P. gingivalis was incorporated into our final experiments to see if this microbe can 
inhibit cisplatin induced apoptosis and necrosis. The cancer cells were infected 
with differing MOI of P. gingivalis (10:1 and 100:1) and the activated caspase-3 
levels were detected by western blot (Fig 12, 13) and human active caspase- 3 
ELISA (Fig 14, 15) whereas LDH levels were detected as described above (Fig 16, 
17).  
 
Western Blot–  
 
Fig 12. P. gingivalis inhibits levels of cleaved caspase-3 sub-units. 
Western blot of whole cell lysates from P. gingivalis-infected (MOI – 100:1) and 
non-infected esophageal squamous cell carcinoma cells (EC9706). Blot was probed 


























































































































































































































































































































































Fig 13. Densitometric quantification of caspase-3 levels of EC9706 cells treated 
with cisplatin 10µM for (30, 36, 42, 48h) with and without P. gingivalis. 
Densitometric quantification was performed by determination of the ratios of (a) 
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uncleaved caspase-3 (b) cleaved caspase-3 to total β-Actin signal using Image J 
software.  Pg - P. gingivalis 
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Fig 14. P. gingivalis inhibits apoptosis in EC9706 cell line.  
ELISA of whole cell lysates (40µg protein) from P. gingivalis infected and non-
infected EC9706 cells. The cells were infected with P. gingivalis at MOI (100:1) and 
incubated for24h prior to treatment with cisplatin 10µM. Level of apoptosis was 
determined using the human active caspase-3 immunoassay. Data are presented 
as the mean ± standard error of three individual experiments. (Pg – P. gingivalis, 





















































































































































2 0 0 0 0
4 0 0 0 0
6 0 0 0 0
















Fig 15. P. gingivalis inhibits apoptosis in EC9706 cell line.  
ELISA of whole cell lysates (40µg protein) from P. gingivalis infected and non-
infected EC9706 cells. The cells were infected with P. gingivalis at MOI (10:1) and 
incubated for24h prior to treatment with cisplatin 10µM. Level of apoptosis was 
determined using the human active caspase-3 immunoassay. (nd – not detectable, 
Pg – P. gingivalis, Cisp - cisplatin) 
 






















































































































































* * * *




Fig 16. P. gingivalis inhibits cisplatin induced necrosis. 
LDH activity assay showing decreased production of LDH when EC9706 cells were 
infected with P. gingivalis at MOI of 10:1 prior to treatment with cisplatin 10µM 
for 12, 24, 36, 48 and 60h. Data are presented as the mean ± standard error of 




































































































































































* * * *
 
Fig 17. P. gingivalis inhibits cisplatin induced necrosis. 
LDH activity assay showing decreased production of LDH when EC9706 cells were 
infected with P. gingivalis at MOI of 100:1 prior to treatment with cisplatin 10µM 
for 12, 24, 36, 48 and 60h. Data are presented as the mean ± standard error of 









CHAPTER 4: DISCUSSION 
 
Esophageal squamous cell carcinoma is a major health problem worldwide and 
has several causative risk factors. It is a growing health concern that is expected 
to increase in incidence over the next 10 years (Napier et al., 2014). Like other 
parts of the gastrointestinal tract, the esophagus hosts a variety of bacteria (Gall 
et al., 2015). While environmental factors, host genetics and immune response 
have been implicated in the progression to esophageal carcinoma, studies 
investigating esophageal microbial communities suggest that bacteria may also 
play an important role in driving the inflammation that leads to disease (Kaakoush, 
Castano-Rodriguez, Man, & Mitchell, 2015). Association between microbes and 
cancer has been established in the past. P. gingivalis has been found in 
significantly higher levels in oral squamous cell carcinoma surfaces as compared 
to the healthy oral mucosa (Nagy, Sonkodi, Szoke, Nagy, & Newman, 1998). 
Similarly high levels of P. gingivalis antibodies have been detected in gingival 
carcinomas in comparison to the healthy gingival tissue (Katz et al., 2011). These 
findings showed a significant association between oral cancer and P. gingivalis. 
Evidence for a potential role for P. gingivalis in the development of esophageal 
cancer has recently emerged as the microbe and its antigens have been detected 
significantly higher in the esophageal cancerous and adjacent tissue in comparison 
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to the normal esophageal mucosa (Gao et al., 2016). Cisplatin, a well-known 
chemotherapeutic drug has been used for the treatment of numerous human 
cancers (Dasari & Tchounwou, 2014) including esophageal cancer. It is known to 
act by inducing apoptosis in the cancer cells. Based on the histological similarity 
between the oral squamous cells and the esophageal squamous cells, this thesis 
investigates if P. gingivalis can inhibit the apoptosis of the esophageal cancer cells 
caused by the chemotherapeutic drug, cisplatin. Studies have shown that P. 
gingivalis inhibits apoptosis in gingival epithelial cells (Nakhjiri et al., 2001). It has 
previously been established that P. gingivalis produces a nucleoside diphosphate 
kinase (NDK) that can promote epithelial cell survival by hydrolyzing extracellular 
ATP and preventing apoptosis (Choi et al., 2013). P. gingivalis can inhibit 
chemically induced apoptosis in gingival epithelial cells by upregulating JAK/Stat 
pathway and blocking activation of the effector caspase-3 (Mao et al., 2007). 
However the potential mechanisms by which the important oral pathogen may 
predispose to the development of esophageal cancer are entirely unknown. We 
show for the very first time, P. gingivalis is capable of inhibiting drug induced 
apoptosis as well as necrosis (atleast the LDH release) in the esophageal squamous 
cell carcinoma cell line EC0706. The best recognized biochemical hallmark of both 
early and late stages of apoptosis is the activation of cysteine proteases 
(caspases). Specifically detection of active caspase-3 in cells and tissue is an 
important method for apoptosis (Choudhary, Al-Harbi, & Almasan, 2015). Thus we 
employed detection of cleaved capsease-3 by western blot and enzyme linked 
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immunosorbent assay. Plasma membrane damage causes leakage of a soluble 
cytoplasmic enzyme, lactate dehydrogenase whose detection can be used as a 
convenient method for detection of necrosis. (Chan, Moriwaki, & De Rosa, 2013). 
The significance of measuring LDH is that the LDH release does not purely occur 
during necrosis but might be released by some cells undergoing apoptosis too. The 
apoptosis seen in the results might not be clean apoptosis and thus LDH release 
as well as cleaved caspase-3 were detected in the cancer cells after cisplatin 10µM 
exposure for 48h. Hence LDH assay was used for detection of necrosis. We found 
that Cisplatin induces apoptosis and necrosis of EC9706 cells in a dose and time 
dependent manner. But when the cancer cells are infected with P. gingivalis prior 
to the treatment with cisplatin, both apoptosis and necrosis is significantly 
reduced. P. gingivalis might also be causing cleavage of caspase-3 into subunits 
that are not active forms for apoptosis as seen by western blot. This finding may 
aid in the understanding of why chemotherapeutic drug action might be rendered 
ineffective in patients with esophageal squamous cell carcinoma and bad 
periodontal health. Improved oral hygiene and treatment of periodontitis may be 
useful in limiting the development or spread of cancer. With a clear need for 
better therapeutics and preventive strategies for esophageal cancer, P. gingivalis 
would serve as a good candidate for further exploration based on its capabilities 




Future direction – Further exploration would be needed, If P. gingivalis leads to 
dysbiosis of the esophageal microbiota involved in the development of 
esophageal cancer. Also the mechanism of how P. gingivalis alters the cancer cell 
morphology and their response to chemotherapeutic agents need to be studied. 
Antibiotics targeted towards P. gingivalis which could combat this inhibition of 
apoptosis and progression of esophageal cancer could definitely be a good area of 
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